Am J Transplant, Volume 18, Suppl 3 Archives - Page 199 of 211 - ATC Abstracts

2018 American Transplant Congress
Combination Proteasome Inhibition and Anti-BAFF Therapy Permits Highly Sensitized Rhesus Kidney Transplantation
B. Ezekian, J. Kwun, M. Manook, P. Schroder, J. Yoon, M. Mulvihill, K. Freischlag, J. Park, J. Cochran, K. Kroning, J. Yi, S. Knechtle.
Duke Transplant Center, Duke University Medical Center, Durham, NC.
Purpose:HLA-sensitization is a significant immunologic barrier to successful kidney transplantation (KT). We have shown that proteasome inhibition (PI) in insolation reduces plasma cells (PCs), but…
2018 American Transplant Congress
CTLA4-Ig and Bortezomib Successfully Reverses Established DSA Responses in Allograft-Sensitized Recipients
D. Jain,¹ J. Young,¹ D. Yin,¹ R. Pelletier,² A. Chong.¹
¹Department or Surgery, University of Chicago, Chicago, IL; ²Department of Surgery, Ohio State University, Columbus, OH.
Background: Sensitized recipients have lower rates of transplantation and poorer outcomes. We and others have reported that the delayed administration of CTLA4-Ig can disrupt fully-established…
2018 American Transplant Congress
Prolonged Cold Ischemia Storage of Renal Allografts Shifts DSA Specificity and Enchances Glomerular Injury
V. Gorbacheva, R. Fan, W. Baldwin, A. Valujskikh.
Immunology, Cleveland Clinic, Cleveland, OH.
Prolonged cold ischemia storage (CIS) of donor organs is a major risk factor for acute and chronic graft injury. The goal of this study was…
2018 American Transplant Congress
Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss
R. Sapir-Pichhadze,¹ X. Zhang,¹ A. Ferradji,¹ A. Madbouly,² S. Fingerson,² K. Tinckam,⁵ H. Gebel,³ H. Cardinal,⁴ B. Foster.¹
¹McGill University, Montreal, Canada; ²National Marrow Donor Program, Minneapolis; ³Emory University Hospital, Atlanta; ⁴CHUM, Montreal, Canada; ⁵University Health Network, Toronto, Canada.
Introduction: HLA matching at the epitope level offers new opportunities to identify compatible donors for transplant candidates. HLAMatchmaker deduces B-cell epitope ('eplets' in HLAMatchmaker) mismatches…
2018 American Transplant Congress
Relationship between Living Kidney Donor Follow-Up GFR and Recipient Graft Loss
C. Holscher,¹ T. Ishaque,¹ C. Haugen,¹ S. DiBrito,¹ K. Jackson,¹ A. Muzaale,¹ A. Massie,^1,2 M. Henderson,¹ J. Garonzik Wang,¹ D. Segev.^1,2,3
¹Johns Hopkins School of Medicine, Baltimore; ²Johns Hopkins School of Public Health, Baltimore; ³Scientific Registry of Transplant Recipients, Minneapolis.
In living kidney transplantation, it is reasonable to believe a donated kidney's function would be associated with the function of the donor's remaining kidney. Indeed,…
2018 American Transplant Congress
The Impact of Donor Specific Alloantibodies on Long-Term Outcomes of Liver Re-Transplantation
Q. Xu,¹ A. Skaro,² V. McAlister.²
¹Department of Pathology and Lab Medicine, University of Western Ontario, London, ON, Canada; ²Department of Surgery, University of Western Ontario, London, ON, Canada.
Despite reports that associate donor specific antibody (DSA) with rejection after liver transplantation, grafts are still allocated according to blood group (ABO) but not human…
2018 American Transplant Congress
Waiting for the Optimal Donor for MCS Patients Awaiting Heart Transplant
J. Kobashigawa, J. Patel, E. Kransdorf, R. Levine, S. Dimbil, E. Passano, L. Czer, J. Moriguchi, F. Arabia.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Patients (pts) bridged with mechanical circulatory support (MCS) may require more optimal donors for best outcome compared to non-bridged transplant recipients. MCS pts have…
2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
J. Dann, A. Agarwal, M. Bradley, J. Geyston, W. Ally.
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…
2018 American Transplant Congress
Chronic Antibody Mediated Rejection in Renal Allografts Shows RNA Transcript Patterns That Evolve with Stage
A. Rosales,¹ B. Adam,² M. Mengel,² T. Oura,¹ M. Matsunami,¹ T. Kawai,¹ A. Cosimi,¹ R. Smith,¹ R. Colvin.¹
¹Massachusetts General Hospital, Boston, MA; ²University of Alberta, Edmonton, AB, Canada.
Purpose. Four stages of chronic antibody mediated rejection (CAMR) in renal allografts have been defined in humans and non-human primates (NHP), beginning with donor specific…
2018 American Transplant Congress
Tacrolimus and Isavuconazole Therapy: What about the Drug Interaction?
C. Gill,¹ N. Mercuro,¹ R. Kenney,¹ A. Jantz,¹ B. Summers,¹ N. Sulejmani,¹ S. Davis.^1,2
¹Henry Ford Hospital, Detroit; ²Wayne State University, Detroit, MI.
Introduction:Isavuconazole (ISV) is a triazole antifungal that is often utilized in solid organ transplant recipients (SOTR) for the treatment of invasive aspergillosis and mucormycosis. Isavuconazole…